dsm-firmenich completes shareholding increase in Andre Pectin to 90.5% Press Release dsm-firmenich completes shareholding increase in Andre Pectin to 90.5% Kaiseraugst (Switzerland), Maastricht (Netherlands), April 3, 2025 dsm-firmenich, innovators in nutrition, health, and beauty, today expanded its investment in Yantai DSM Andre Pectin Company Limited (‘Andre Pectin’), increasing its shareholding to 90.5%. Andre Pectin is a leading specialty food ingredient producer. dsm-firmenich already held 75% of shares in Andre Pectin. Following the latest acquisition of another 15.5% of shares, ...
IBA signs contract for a Proteus®ONE solution to be installed at the Tri-Service General Hospital in Taiwan Louvain-La-Neuve, Belgium, April 2nd, 2025 – (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and the world’s leading provider of proton therapy solutions for the treatment of cancer, today announces it has signed a contract for the supply of a Proteus®ONE1 compact proton therapy solution to be located at the Tri-Service General Hospital in Taipei, Taiwan. The contract includes the supply of a Proteus®ONE system and a Quality Assurance...
IBA signe un contrat pour installer une solution Proteus®ONE au Tri-Service General Hospital à Taïwan Louvain-la-Neuve, Belgique, le 2 avril 2025 - IBA (Ion Beam Applications S.A., EURONEXT), le leader mondial des technologies d’accélération de particules et principal fournisseur de solutions de protonthérapie pour le traitement du cancer, annonce aujourd'hui la signature d'un contrat pour la fourniture d'une solution compacte de protonthérapie Proteus®ONE1 au Tri-Service General Hospital à Taipei, Taïwan. Le contrat comprend la fourniture d'un système Proteus®ONE et d'un package d'ass...
Progress on share buyback programme Progress on share buyback programme ING announced today that, as part of our €2.0 billion share buyback programme announced on 31 October 2024, in total 2,754,057 shares were repurchased during the week of 24 March 2025 up to and including 28 March 2025. The shares were repurchased at an average price of €18.58 or a total amount of €51,159,385.70. For detailed information on the daily repurchased shares, individual share purchase transactions and weekly reports, see the ING website at . In line with the purpose of the programme to reduce the share cap...
dsm-firmenich announces share repurchase program to cover share plans and reduce capital Press Release dsm-firmenich announces share repurchase program to cover share plans and reduce capital Kaiseraugst (Switzerland), Maastricht (Netherlands), April 1, 2025 dsm-firmenich, innovators in nutrition, health, and beauty announced on February 13, 2025 its intention to repurchase ordinary shares with an aggregate market value of €1 billion and reduce its issued capital. This share repurchase program will start for an initial €500 million and will be increased to €1 billion upon the completion ...
IBA – ACQUISITION OF OWN SHARES Immediate Release – March 31st, 2025 Louvain-la-Neuve, Belgium, March 31st, 2025 - In accordance with article 8:4 of the Royal Decree of 29 April 2019 executing the Belgian Code on Companies and Associations, Ion Beam Applications SA (“IBA”) hereby discloses information in relation to its share buyback program announced on March 24th, 2025. Under this program, IBA has requested a financial intermediary to repurchase up to 650,000 IBA ordinary shares on its behalf under the terms of a mandate with validity until December 31st, 2025, effective as from Marc...
IBA – ACQUISITION D’ACTIONS PROPRES Publication immédiate – 31 mars 2025 Louvain-la-Neuve, Belgique, 31 mars 2025 - Conformément à l'article 8:4 de l'arrêté royal du 29 avril 2019 portant exécution du Code belge des sociétés et associations, Ion Beam Applications SA ("IBA") communique par la présente certaines informations relatives à son programme de rachat d'actions annoncé le 24 mars 2025. Dans le cadre de ce programme, IBA a demandé à un intermédiaire financier de racheter en son nom un maximum de 650.000 actions ordinaires IBA selon les termes d'un mandat valable jusqu'au 31 décem...
Hyloris entered into a late-stage research and development program in collaboration with AFT to introduce an injectable iron deficiency therapy (HY-094) to the global market – development costs and net margin from sales and licensing will be distributed equally. This announcement brings a new later stage product to the company's pipeline, for which Hyloris expects phase 3 development to start in the near-term. Given the size of the market, we expect this will be a high volume product and Hyloris...
This note gathers feedback from the group meetings and the panels. In total 21 companies were presented in group meetings and/or panels. More than 100 guests found their way to the venue either physical or virtual (only panels). The 2 panels made for informative additions to the C-level meetings and a nice platform for discussion. Wednesday afternoon concentrated 4 experts from Logistic companies (CTP, Montea, VGP, WDP) for an interesting discussion on brownfields: " an answer to the scarcity of...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.